I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced that it will present clinical data from a Phase 2 study of lemzoparlimab (TJC4) combined with azacitidine for higher risk myelodysplastic syndrome (HR-MDS) at the ESMO Congress 2022, scheduled from September 9-13, 2022. The abstract, titled Lemzoparlimab in Combination with Azacitidine in Patients with HR-MDS (Abstract #3823), highlights initial clinical results. This study represents a significant step in I-Mab's ongoing research into innovative cancer therapies, following its collaboration with AbbVie for global development.

Positive

• Presentation of Phase 2 clinical data suggests promising advancements for lemzoparlimab.
• Potential for lemzoparlimab to improve treatment for HR-MDS patients.
• Collaboration with AbbVie enhances development and commercialization prospects.

Negative

• None.

GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data from a Phase 2 study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9 – 13, 2022.

Presentation details:

Abstract Title:	Lemzoparlimab, a Differentiated Anti-CD47 Monoclonal Antibody, in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): Initial Clinical Results
Abstract #:	3823
First author:	Prof. Zhijian Xiao, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences
Session:	Proffered Paper
Date and Time:	Tuesday, September 13, 2022

Please visit the ESMO website here to find more information.

About CD47 and Lemzoparlimab

CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a "don't eat me" signal to otherwise tumor-engulfing macrophages.  CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.

Multiple clinical studies are ongoing in the Americas, Europe, Australia, and Asia to explore indications in treating both hematologic malignancies and solid tumors. Lemzoparlimab is being studied in patients with myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), and advanced solid tumors in combination with chemotherapy and immune checkpoint inhibitors.

In September 2020, I-Mab and AbbVie entered into a global strategic collaboration to develop and commercialize lemzoparlimab. This includes the design and conduct of further clinical trials to evaluate lemzoparlimab in multiple cancers in China and globally.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into an innovative global specialty biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.  For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

I-Mab Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from the lemzoparlimab clinical studies, the potential implications of clinical data for patients, and I-Mab's advancement of, and anticipated clinical development, regulatory milestones, and commercialization of lemzoparlimab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company's clinical development, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the US Securities and Exchange Commission. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

I-Mab Contacts

Richard Yeh Chief Operating Officer IR@i-mabbiopharma.com	Gigi Feng Chief Communications Officer PR@i-mabbiopharma.com

Investor Inquiries

The Piacente Group, Inc. Emilie Wu E-mail: emilie@thepiacentegroup.com Office line: +86 21 6039 8363

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-present-phase-2-clinical-data-of-cd47-antibody-lemzoparlimab-at-esmo-congress-2022-301588015.html

SOURCE I-Mab

FAQ

What clinical data will I-Mab present at the ESMO Congress 2022?

I-Mab will present data from a Phase 2 study of lemzoparlimab combined with azacitidine for treating higher risk myelodysplastic syndrome.

When is I-Mab's presentation scheduled?

The presentation is scheduled for September 13, 2022, at the ESMO Congress.

What is lemzoparlimab?

Lemzoparlimab is a differentiated anti-CD47 monoclonal antibody designed to target tumor cells while minimizing side effects on red blood cells.

Who is the first author of the abstract being presented?

Prof. Zhijian Xiao from the Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, is the first author.

What is the significance of the ESMO Congress for I-Mab?

The ESMO Congress provides a platform to showcase I-Mab's advancements in developing lemzoparlimab, potentially attracting investor interest and enhancing its market presence.